C. Coleman

发表

Real-time magnetic resonance image-guided interstitial brachytherapy in the treatment of select patients with clinically localized prostate cancer.

A. D'Amico, R. Cormack, C. Tempany, 1998, International journal of radiation oncology, biology, physics.

Effect of cell cycle stage, dose rate and repair of sublethal damage on radiation-induced apoptosis in F9 teratocarcinoma cells.

C. Coleman, R. E. Langley, S. Quartuccio, 1995, Radiation research.

Beneficial liaisons: radiobiology meets cellular and molecular biology.

C. Coleman, 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Biologic basis for radiation oncology.

C. Coleman, M. Stevenson, 1996, Oncology.

Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer.

A. Renshaw, A. D'Amico, Ming-Hui Chen, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of prostate and seminal vesicle motion: implications for treatment planning.

P Kijewski, D. Gladstone, C. Coleman, 1996, International journal of radiation oncology, biology, physics.

Elevation of mouse kidney thiol content following administration of glutathione.

C. Coleman, E. Bump, R. Al-Sarraf, 1992, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Alternative and future strategies in the treatment of malignant gliomas

P. Wen, C. Coleman, H. Fine, 1991 .

Apoptosis and clonogenic cell death in PC3 human prostate cancer cells after treatment with gamma radiation and suramin.

C. Coleman, B. Teicher, S. T. Palayoor, 1997, Radiation research.

Workshop on partial breast irradiation: state of the art and the science, Bethesda, MD, December 8-10, 2002.

H. Bartelink, C. Coleman, A. Giuliano, 2004, Journal of the National Cancer Institute.

COMMENTARY Workshop on Partial Breast Irradiation: State of the Art and the Science, Bethesda, MD,

H. Bartelink, C. Coleman, A. Giuliano, 2004 .

Urologic oncology: extraordinary opportunities for discovery

C. Coleman, 2001 .

5 year biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer

A. D'Amico, D. Schultz, I. Kaplan, 1998 .

Interaction of SR-4233 with hyperthermia and radiation in the FSaIIC murine fibrosarcoma tumor system in vitro and in vivo.

C. Coleman, B. Teicher, T. Herman, 1990, Cancer research.

Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.

C. Coleman, B. Teicher, G. Bubley, 1991, Cancer research.

Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma.

C. Coleman, B. Teicher, T. Herman, 1992, Journal of the National Cancer Institute.

Career Options in Radiation Oncology

C. Coleman, 2021 .

Molecular biology in radiation oncology. Radiation oncology perspective of BRCA1 and BRCA2.

C. Coleman, 1999, Acta oncologica.

Analyzing local and distant recurrence (Reply)

R. Gelber, C. Coleman, R. Gelman, 1990 .

Chemical modifiers of cancer treatment.

C. Coleman, E. Bump, R. Kramer, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Beneficial liaisons: radiobiology meets cellular and molecular biology

C. Coleman, 1993 .

Results of stereotactic brachytherapy used in the initial management of patients with glioblastoma.

P. Wen, H. Kooy, C. Coleman, 1990, Journal of the National Cancer Institute.

A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma.

C. Coleman, S. Pomeroy, P. Barnes, 2003, International journal of radiation oncology, biology, physics.

Clinical trials with hypoxic cell sensitizers: time to retrench or time to push forward?

C. Coleman, T. Phillips, T. Wasserman, 1984, International journal of radiation oncology, biology, physics.

Secondary neoplasms in patients treated for cancer: etiology and perspective.

C. Coleman, 1982, Radiation research.

Phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer.

C. Coleman, C. Beard, D. Johnson, 1994, International journal of radiation oncology, biology, physics.

Clinical radiosensitization: why it does and does not work.

C. Coleman, J. Mitchell, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Transitioning to Environmentally Sustainable, Climate-Smart Radiation Oncology Care.

C. Coleman, M. Abdel-Wahab, R. Chuter, 2022, International journal of radiation oncology, biology, physics.

Splenic injury caused by therapeutic irradiation

C. Coleman, L. F. Fajardo, M. Dailey, 1981, The American journal of surgical pathology.

Interaction of tomudex with radiation in vitro and in vivo.

C. Coleman, A. Recht, B. Teicher, 1998, International journal of oncology.

Pharmacodynamics of prolonged treatment with L,S-buthionine sulfoximine.

C. Coleman, E. Bump, O. Griffith, 1994, International Journal of Radiation Oncology, Biology, Physics.

The use of probenecid as a chemoprotector against cisplatin nephrotoxicity

C. Coleman, B. Sikic, C. Jacobs, 1991, Cancer.

Pilot study of local hyperthermia, radiation therapy, etanidazole, and cisplatin for advanced superficial tumours.

C. Coleman, B. Teicher, G. Svensson, 1995, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

Initial pharmacology and toxicology of intravenous desmethylmisonidazole.

C. Coleman, T. Phillips, J. Schwade, 1982, International journal of radiation oncology, biology, physics.

Phase I trial of the hypoxic cell radiosensitizer SR-2508: the results of the five to six week drug schedule.

C. Coleman, S. Hancock, T. Wasserman, 1986, International journal of radiation oncology, biology, physics.

Initial report of the phase I trial of the hypoxic cell radiosensitizer SR-2508.

C. Coleman, S. Hancock, J. Harris, 1984, International journal of radiation oncology, biology, physics.

Novel concepts in modification of radiation sensitivity.

C. Coleman, S. T. Palayoor, R. E. Langley, 1994, International journal of radiation oncology, biology, physics.

Radiation-induced apoptosis in F9 teratocarcinoma cells.

C. Coleman, S. T. Palayoor, R. E. Langley, 1994, International journal of radiation biology.

Secondary malignancy after treatment of Hodgkin's disease: an evolving picture.

C. Coleman, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The hall-mark of modern radiation oncology.

C. Coleman, M. Stevenson, 1994, International journal of radiation oncology, biology, physics.

Role of additional radiotherapy in advanced stages of Hodgkin's disease.

V. Diehl, T. Lister, C. Coleman, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Sensitization of Chinese hamster ovary cells to melphalan by etanidazole under intermittent hypoxia.

C. Coleman, E. Bump, D. McGinnis, 1992, International journal of radiation oncology, biology, physics.

Final report of the phase I trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) Radiation Therapy Oncology Group 83-03.

C. Coleman, S. Hancock, T. Phillips, 1990, International journal of radiation oncology, biology, physics.

We're from the Government and We're Here to Help You

C. Coleman, R. Cumberlin, 1994, International journal of radiation oncology, biology, physics.

Training the radiation oncologist for the twenty-first century.

C. Coleman, J. Cooper, L. Prosnitz, 1996, International journal of radiation oncology, biology, physics.

RTOG #89-06: a phase I study to evaluate intraoperative radiation therapy and the hypoxic cell sensitizer etanidazole in locally advanced malignancies.

C. Coleman, D. Nagorney, R. D. Noyes, 1994, International journal of radiation oncology, biology, physics.

Chemoradiation and adjuvant chemotherapy for glioblastoma: why does so much therapy yield so little improvement in survival?

C. Coleman, D. Shrieve, J. Loeffler, 1995, International journal of radiation oncology, biology, physics.

Improved methodology for analyzing local and distant recurrence.

R. Gelber, C. Coleman, R. Gelman, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Modifiers of radiation-induced apoptosis.

C. Coleman, S. T. Palayoor, R. E. Langley, 1993, Radiation research.

The current status of drug development of hypoxic cell radiosensitizers and their potential role in gynecologic oncology.

C. Coleman, A. Martinez, V. Hirst, 1984, Gynecologic oncology.

Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy.

M. Kaminski, C. Coleman, S. Rosenberg, 1986, Annals of internal medicine.

A phase I study of etanidazole and radiotherapy in malignant glioma.

P. Wen, P. Black, C. Coleman, 1994, International journal of radiation oncology, biology, physics.

Mentors, mensches, and models.

C. Coleman, T. Wasserman, 2009, International journal of radiation oncology, biology, physics.

Hypoxia in tumors: a paradigm for the approach to biochemical and physiologic heterogeneity.

C. Coleman, C N Coleman, 1988, Journal of the National Cancer Institute.

Sensitizers and protectors of radiation and chemotherapy.

C. Coleman, J. Mitchell, M. Poggi, 2001, Current problems in cancer.

Radiation and chemotherapy sensitizers and protectors.

C. Coleman, A. Turrisi, 1990, Critical reviews in oncology/hematology.

Estimating the risk of second primary tumors following cancer treatment.

C. Coleman, J. Harris, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lisofylline as a modifier of radiation therapy.

C. Coleman, R. Herbst, B. Teicher, 1996, Oncology research.

Combined-modality therapy of esophageal cancer with radiotherapy, etanidazole, and cisplatin-fluorouracil, with or without surgery: neurotoxicity, other toxicities and outcome.

C. Coleman, A. Recht, P. Busse, 1994, International journal of radiation oncology, biology, physics.

Modulation of radiation-induced apoptosis and G2/M block in murine T-lymphoma cells.

C. Coleman, R. Macklis, S. T. Palayoor, 1995, Radiation research.

Enhancement of the clinical activity of melphalan by the hypoxic cell sensitizer misonidazole.

C. Coleman, R. Carlson, B. Sikic, 1988, Cancer research.

Signal transduction inhibitors as modifiers of radiation therapy in human prostate carcinoma xenografts

C. Coleman, B. Teicher, S. T. Palayoor, 1996 .

Distribution of etanidzole into human brain tumors: Implications for treating high grade gliomas

C. Coleman, E. Alexander, J. Loeffler, 1992 .

Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types).

C. Coleman, R. Dorfman, S. Rosenberg, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of OH scavenging on the yield of radiation-induced DNA double-strand breaks in isolated nuclei.

L. Chin, C. Coleman, C. Obcemea, 1988, Basic life sciences.

Of what use is molecular biology to the practicing radiation oncologist?

C. Coleman, C. Norman Coleman, 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Stage IA and IIA supradiaphragmatic Hodgkin's disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation.

C. Coleman, B. Silver, D. Rosenthal, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Advances in cellular and molecular radiation oncology.

C. Coleman, M. Stevenson, C. Norman Coleman, 1996, Urologic oncology.

Hypoxic cell radiosensitizers: expectations and progress in drug development.

C. Coleman, C N Coleman, 1985, International journal of radiation oncology, biology, physics.

Survival results from a phase I study of etanidazole (SR2508) and radiotherapy in patients with malignant glioma.

P. Wen, P. Black, C. Coleman, 1998, International journal of radiation oncology, biology, physics.

Rate of relapse following treatment for localized prostate cancer: a critical analysis of retrospective reports.

P. Kantoff, C. Coleman, R. Gelman, 1994, International journal of radiation oncology, biology, physics.

Carcinoma of the prostate: praising Stanford's accomplishments.

C. Coleman, 1994, International journal of radiation oncology, biology, physics.

Prostate cancer. Technology versus biology

C. Coleman, Irving D. Kaplan, 1993, Cancer.

The challenge for conformal therapy for prostate cancer.

C. Coleman, C. Beard, I. Kaplan, 1993, International journal of radiation oncology, biology, physics.

Alpha particle radio-immunotherapy: animal models and clinical prospects.

C. Coleman, R. Macklis, J. Ferrara, 1989, International journal of radiation oncology, biology, physics.

Antiangiogenic agents can increase tumor oxygenation and response to radiation therapy

C. Coleman, B. Teicher, B. Dupuis, 1994 .

Chemical modifiers of radiation and chemotherapy: tumor sensitization and normal tissue protection

C. Coleman, T. Wasserman, 1984 .

Phase I trial of intravenous L-phenylalanine mustard plus the sensitizer misonidazole.

C. Coleman, T. Phillips, S. Leibel, 1983, Cancer research.

Rationale for use of local hyperthermia with radiation therapy and selected anticancer drugs in locally advanced human malignancies.

T S Herman, Jennifer Hayes Clark, C. Coleman, 1988, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

Results of a phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer (RTOG Protocol 90-20).

C. Coleman, J. Forman, J. Buzydlowski, 1996, International journal of radiation oncology, biology, physics.

Logistics in designing clinical trials for etanidazole (SR 2508): an RTOG experience.

C. Coleman, P. Rubin, T. Phillips, 1992, International journal of radiation oncology, biology, physics.

CHAPTER 12 CYTOGENETIC BIODOSIMETRY

C. Coleman, 2012 .

Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile.

C. Coleman, S. Hancock, T. Blaschke, 1987, Cancer research.

CLINICAL TRIALS OF ETANIDAZOLE (SR 2508): RTOG AND JOINT CENTER FOR RADIATION THERAPY TRIALS

C. Coleman, S. Hurwitz, D. Lee, 1992 .

Initial results of a phase I trial of continuous infusion SR 2508 (etanidazole): a radiation therapy oncology group study.

C. Coleman, J. Harris, R. Kramer, 1989, International journal of radiation oncology, biology, physics.

Pharmacokinetic monitoring and dose modification of etanidazole in the RTOG 85-27 phase III head and neck trial.

C. Coleman, T. Pajak, J. Stetz, 1997, International journal of radiation oncology, biology, physics.

Radioimmunotherapy with alpha-particle-emitting immunoconjugates.

C. Coleman, S. Adelstein, R. Macklis, 1988, Science.

CT of irradiated solid tumor metastases to the brain

C. Coleman, D. Enzmann, P. Eifel, 1982, Neuroradiology.

Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors.

C. Coleman, J. Loeffler, L. Shulman, 1999, International journal of radiation oncology, biology, physics.

Muscle cramping in phase I clinical trials of tirapazamine (SR 4233) with and without radiation.

C. Coleman, S. Hancock, S. Senan, 1994, International journal of radiation oncology, biology, physics.

Use of the hypoxic cell sensitizer etanidazole (SR-2508) with intravenous melphalan and prednisone in the treatment of multiple myeloma: a pharmacokinetic study.

L. Kalish, C. Coleman, L. Shulman, 1994, International journal of radiation oncology, biology, physics.

Phase I pharmacokinetic study of the hypoxic cell sensitizer etanidazole with carboplatin and cyclophosphamide in the treatment of advanced ovarian cancer.

L. Kalish, C. Coleman, B. Teicher, 1994, International journal of radiation oncology, biology, physics.

Protection against SR 4233 (Tirapazamine) aerobic cytotoxicity by the metal chelators desferrioxamine and tiron.

C. Coleman, F. Gonzalez, M. Krishna, 1994, International journal of radiation oncology, biology, physics.

Technology-enabled activation of skin cancer screening for hematopoietic cell transplantation survivors and their primary care providers (TEACH)

A. Marghoob, K. Emmons, C. Coleman, 2020, BMC Cancer.

SR-4233 (Tirapazamine) acts as an uncoupler of oxidative phosphorylation in human MCF-7 breast carcinoma cells.

C. Coleman, B. Teicher, G. Ara, 1994, Cancer letters.

Minimal long-term cardiopulmonary dysfunction following treatment for Hodgkin's disease.

T. Raffin, C. Coleman, R. Hoppe, 1987, International journal of radiation oncology, biology, physics.

Current scientific issues related to clinical radiation oncology.

C. Coleman, J. Harris, 1998, Radiation research.

Stereotactic radiosurgery for intracranial arteriovenous malformations using a standard linear accelerator.

R L Siddon, K. Winston, C. Coleman, 1989, International journal of radiation oncology, biology, physics.

Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml.

A. D'Amico, I. Kaplan, C. Coleman, 1997, International journal of radiation oncology, biology, physics.

Inhibition of c/s-Diamminedichloroplatinum Secretion by the Human Kidney with Probenecid1

M. Weiner, C. Coleman, C. Jacobs, 2006 .

Inhibition of cis-diamminedichloroplatinum secretion by the human kidney with probenecid.

M. Weiner, C. Coleman, C. Jacobs, 1984, Cancer research.

Role of interstitial radiotherapy in the management of clinically organ-confined prostate cancer: the jury is still out.

A. D'Amico, C. Coleman, A V D'Amico, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final report of the phase I trial of continuous infusion etanidazole (SR 2508): a Radiation Therapy Oncology Group study.

P. Wen, C. Coleman, E. Alexander, 1992, International Journal of Radiation Oncology, Biology, Physics.

The efficacy of pharmacokinetic monitoring and dose modification of etanidazole on the incidence of neurotoxicity: results from a phase II trial of etanidazole and radiation therapy in locally advanced prostate cancer.

C. Coleman, M. Rose, L. Buswell, 1992, International journal of radiation oncology, biology, physics.

Effects of nitroimidazoles on neuronal cells in vitro.

C. Coleman, M. Stevenson, S. Calderwood, 1989, International journal of radiation oncology, biology, physics.

Pharmacology and toxicology of desmethylmisonidazole (DMM) - An hypoxic cell sensitizer

C. Coleman, T. Phillips, T. Wasserman, 1982 .

Bioreductive metabolism of SR-4233 (WIN 59075) by whole cell suspensions under aerobic and hypoxic conditions: role of the pentose cycle and implications for the mechanism of cytotoxicity observed in air.

C. Coleman, C. Koch, J. Mitchell, 1994, International journal of radiation oncology, biology, physics.

"Reports of my death [may be] greatly exaggerated" (adapted from Mark Twain)--in response to Dr. J. M. Brown, IJROBP 32:883-885; 1995.

C. Coleman, 1995, International journal of radiation oncology, biology, physics.

Modification of the aerobic cytotoxicity of etanidazole.

C. Coleman, S. T. Palayoor, R. E. Langley, 1994, International journal of radiation oncology, biology, physics.

Modulating the Radiation Response

C. Coleman, 1996, Stem cells.

Effect of BSO and etanidazole on neurofilament degradation in neonatal rat spinal cord cultures.

C. Geula, C. Coleman, S. T. Palayoor, 1996, The British journal of cancer. Supplement.

7 Hypoxic Cell Sensitizers

C. Coleman, 1991 .

Hypoxic Cell Sensitizers

C. Coleman, 1990 .

Phase III study of ibuprofen versus placebo for radiation-induced genitourinary side effects.

J. Manola, I. Kaplan, C. Coleman, 2002, International journal of radiation oncology, biology, physics.

Re: The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients.

C. Coleman, I. Kaplan, 1994, The Journal of urology.

Inflammatory breast issue.

C. Coleman, J. Abrams, P. Wallner, 2003, Journal of the National Cancer Institute.

Analysis of prostate and seminal vesicle motion

C. Coleman, P. Kijewski, M. Bussière, 1993 .

Equivalent 5-year bNED in select prostate cancer patients managed with surgery or radiation therapy despite exclusion of the seminal vesicles from the CTV.

A. D'Amico, D. Schultz, I. Kaplan, 1997, International journal of radiation oncology, biology, physics.

Tumor oxygenation after hyperthermia in the rat 13762 mammary carcinoma and the DU-145 human prostate carcinoma.

C. Coleman, B. Teicher, G. Ara, 1997, International Journal of Oncology.

The effect of vitamin B6 on the neurotoxicity and pharmacology of desmethylmisonidazole and misonidazole: clinical and laboratory studies.

C. Coleman, V. Hirst, J. Halsey, 1984, International journal of radiation oncology, biology, physics.

The development of an oral prodrug, SR-2545, of the 2-nitroimidazole radiosensitizer SR-2508.

C. Coleman, L. Constine, W. Lee, 1982, International journal of radiation oncology, biology, physics.

DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity

C. N. Coleman, C. Coleman, C. Coleman, 2017, Nature Communications.

Effects of radiation on normal tissue: consequences and mechanisms.

C Norman Coleman, C. N. Coleman, C. Coleman, 2003, The Lancet. Oncology.

International Conference on Translational Research ICTR 2003 Conference Summary: marshalling resources in a complex time.

C. N. Coleman, C. Coleman, 2004, International journal of radiation oncology, biology, physics.

Preclinical Data on Efficacy of 10 Drug-Radiation Combinations: Evaluations, Concerns, and Recommendations1

James B. Mitchell, James Deye, Jacek Capala, 2016, Translational oncology.

Premenopausal breast cancer patients treated with conservative surgery, radiotherapy and adjuvant chemotherapy have a low risk of local failure.

C. Coleman, S. Schnitt, A. Recht, 1989, International journal of radiation oncology, biology, physics.

Decreasing the Toxicity of Radiation Therapy: Radioprotectors and Radiomitigators Being Developed by the National Cancer Institute Through Small Business Innovation Research Contracts.

C. N. Coleman, D. Narayanan, B. Vikram, 2019, International journal of radiation oncology, biology, physics.

NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.

C. N. Coleman, P. Okunieff, W. Curran, 2013, Journal of the National Cancer Institute.

Radiation Oncology in the 21st Century: Prospective Randomized Trials That Changed Practice… or Didn’t!

C. N. Coleman, B. Vikram, C. Coleman, 2018, Front. Oncol..

Linking radiation oncology and imaging through molecular biology (or now that therapy and diagnosis have separated, it's time to get together again!).

C. N. Coleman, C. Coleman, 2003, Radiology.

Inverse treatment planning based on MRI for HDR prostate brachytherapy.

Peter Guion, Jean Pouliot, Holly Ning, 2005, International journal of radiation oncology, biology, physics.